Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
Would you consider lenvatinib plus everolimus as first line treatment for a patient with tuberous sclerosis and metastatic renal cell carcinoma?
Related Questions
What is your approach to muscle-invasive bladder cancer in a patient who is ineligible for surgery and radiotherapy?
What factors do you use when selecting which NGS platform to use for sequencing solid tumors?
How do you manage dysgeusia from Enfortumab Vedotin?
What is your preferred initial systemic therapy approach to metastatic clear cell adenocarcinoma of the urethra (CCAU)?
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
How do you manage anemia associated with belzutifan therapy?
Would the occurrence of obvious tumor rupture/spillage intraoperatively impact your decision for adjuvant systemic therapy after resection of either clear cell RCC or papillary RCC?
Would you consider enfortumab vedotin + pembrolizumab prior to surgery for a patient with urothelial carcinoma with regional nodes who is not eligible for neoadjuvant cisplatin?
For patients with oligo-progressive prostate cancer fit for metastasis-directed therapy but ineligible for radiotherapy or surgery, how do you decide between the types of ablation available?
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?
